Samuel S Engel Selected Research

Body Weight (Weight, Body)

10/2023	A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.
1/2019	Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin.
2/2018	Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study.
2/2018	Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study.
2/2018	Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study.
1/2018	Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.
1/2018	Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
11/2017	A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin.
11/2017	A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes.
9/2016	A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Samuel S Engel Research Topics

Disease

71	Type 2 Diabetes Mellitus (MODY) 01/2022 - 04/2010
29	Hypoglycemia (Reactive Hypoglycemia) 11/2020 - 04/2010
15	Body Weight (Weight, Body) 10/2023 - 07/2011
6	Cardiovascular Diseases (Cardiovascular Disease) 11/2017 - 11/2014
5	Heart Failure 02/2018 - 07/2015
4	Renal Insufficiency (Renal Failure) 10/2020 - 11/2017
4	Infections 11/2019 - 01/2018
4	Chronic Renal Insufficiency 02/2018 - 07/2010
4	Pancreatitis 11/2017 - 01/2013
4	Hyperglycemia 03/2017 - 01/2013
3	Diabetes Mellitus 11/2020 - 11/2017
3	Stroke (Strokes) 02/2018 - 04/2017
3	Weight Gain 10/2017 - 03/2015
3	Diarrhea 01/2017 - 04/2010
2	Weight Loss (Weight Reduction) 10/2023 - 10/2017
2	Overweight 01/2022 - 01/2022
2	Neoplasms (Cancer) 11/2017 - 01/2013
2	Myocardial Infarction 11/2017 - 04/2017
2	Hypertension (High Blood Pressure) 11/2017 - 01/2017
2	Pancreatic Neoplasms (Pancreatic Cancer) 04/2017 - 02/2017
2	Constipation 01/2013 - 04/2010
1	Alcoholic Fatty Liver 10/2023
1	Inflammation (Inflammations) 10/2023
1	Non-alcoholic Fatty Liver Disease 10/2023
1	Insulin Resistance 05/2020
1	Dementia (Dementias) 11/2019
1	Vascular Diseases (Vascular Disease) 10/2018
1	Cardiac Arrhythmias (Arrythmia) 02/2018
1	Peripheral Vascular Diseases (Peripheral Vascular Disease) 02/2018
1	Hypovolemia 02/2018
1	Disease Progression 11/2017
1	Diabetic Neuropathies (Diabetic Neuropathy) 11/2017
1	Bone Fractures (Bone Fracture) 11/2017
1	Eye Diseases (Eye Disease) 11/2017
1	Chronic Kidney Failure (Chronic Renal Failure) 06/2017
1	Unstable Angina 04/2017
1	Hyperlipidemias (Hyperlipidemia) 01/2017
1	Vomiting 01/2017
1	Nausea 01/2017
1	Abdominal Pain (Pain, Abdominal) 01/2017
1	Edema (Dropsy) 09/2016
1	Albuminuria 09/2016
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 10/2013
1	Dyslipidemias (Dyslipidemia) 01/2013

Drug/Important Bio-Agent (IBA)

50	Sitagliptin Phosphate (Januvia)FDA Link 01/2022 - 04/2010
31	Metformin (Glucophage)FDA LinkGeneric 01/2022 - 04/2010
16	Hypoglycemic Agents (Hypoglycemics)IBA 11/2020 - 07/2010
12	2- (2,5- difluorophenyl)- 5- (2- (methylsulfonyl)- 2,6- dihydropyrrolo(3,4- c)pyrazol- 5(4H)- yl)tetrahydro- 2H- pyran- 3- amineIBA 01/2021 - 11/2015
11	Insulin (Novolin)FDA Link 01/2022 - 11/2012
11	Glucose (Dextrose)FDA LinkGeneric 05/2020 - 03/2015
9	Dipeptidyl-Peptidase IV InhibitorsIBA 11/2017 - 03/2015
6	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 11/2020 - 09/2013
6	glimepiride (Amarel)FDA LinkGeneric 01/2019 - 06/2011
6	ertugliflozinIBA 01/2019 - 01/2018
3	Sodium-Glucose Transport ProteinsIBA 02/2018 - 02/2018
2	Glucagon-Like Peptide-1 ReceptorIBA 10/2023 - 04/2010
2	Glucagon Receptors (Glucagon Receptor)IBA 10/2023 - 11/2014
2	AutoantibodiesIBA 01/2022 - 01/2022
2	ipragliflozinIBA 01/2021 - 01/2021
2	dapagliflozinIBA 10/2020 - 12/2018
2	Hemoglobins (Hemoglobin)IBA 05/2020 - 01/2016
2	Insulin Glargine (Lantus)FDA Link 01/2019 - 06/2015
2	Glipizide (Glucotrol)FDA LinkGeneric 06/2017 - 07/2011
2	CreatinineIBA 09/2016 - 07/2010
2	Glucagon (Glukagon)FDA Link 11/2015 - 10/2013
2	Antihypertensive Agents (Antihypertensives)IBA 11/2014 - 07/2010
2	IncretinsIBA 10/2013 - 04/2010
1	semaglutideIBA 10/2023
1	Fatty Acids (Saturated Fatty Acids)IBA 10/2023
1	Glucagon-Like Peptide 1 (GLP 1)IBA 10/2023
1	Long-Acting Insulin (Insulin, Long Acting)FDA Link 11/2019
1	SodiumIBA 12/2018
1	Blood Glucose (Blood Sugar)IBA 02/2018
1	omega-Chloroacetophenone (Mace)IBA 11/2017
1	Acarbose FDA LinkGeneric 01/2017
1	Pioglitazone (Actos)FDA Link 09/2016
1	AlbuminsIBA 09/2016
1	Sodium Potassium Chloride Symporter Inhibitors (Loop Diuretics)IBA 12/2015
1	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 11/2015
1	N- ((4- (1- (3- (3,5- dichlorophenyl)- 5- (6- methoxynaphthalen- 2- yl)- 1H- pyrazol- 1- yl)ethyl)phenyl)carbonyl)- beta- alanineIBA 11/2015
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2013
1	Simvastatin (Zocor)FDA LinkGeneric 01/2013
1	Glyburide (Glibenclamide)FDA LinkGeneric 06/2011
1	Gliclazide (Diamicron)IBA 06/2011
1	LipidsIBA 07/2010
1	2,4-thiazolidinedione (thiazolidinedione)IBA 07/2010
1	Exenatide (Byetta)FDA Link 04/2010

Therapy/Procedure

23	Therapeutics 10/2023 - 04/2010
23	Glycemic Control 01/2022 - 07/2011
1	Time-to-Treatment 11/2014
1	Length of Stay 02/2013
1	Injections 04/2010